Skip to main content

FDA Approvals

Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome

Wayne Kuznar

FDA Approvals, Prostate Cancer

Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer

Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer

Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation

Breast Cancer, FDA Approvals, Oncology

Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer

Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer

Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection

FDA Approvals, Pancreatic Cancer, Oncology

Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Phoebe Starr

Page 18 of 53
Results 171 - 180 of 524